跳至主要内容
临床试验/NCT03841266
NCT03841266已完成不适用

Postoperative Recurrence Risk Evaluation of Hormone Receptor Positive, Her-2 Negative Breast Cancer by Using Different 21-gene Detection Kits (REBCK)

Xijing Hospital1 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2019年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
220
试验地点
1
主要终点
correlation analysis

研究概览

简要总结

Breast cancer patients with early breast cancer were enrolled according to the inclusion criteria. Baseline characteristics were recorded from medical record system. Recurrence score were obtained by 21-gene detection kits from different biological companies. Relationship between recurrence score and the prognosis was explored. Meanwhile, the investigators analyzed the consistency of the results obtained from various 21-gene test kits and immunohistochemistry detection.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • breast cancer in stage I-III, tumor size>0.5cm
  • lymph nodes negative
  • hormone receptor positive (ER+/PR+,ER+/PR-,ER-/PR+)
  • HER2 negative(IHC 0 or +, FISH negative)
  • receive endocrine therapy only
  • enough FFPE samples within 10 years(3~6 10μm )
  • patients with integrated medical records

排除标准

  • Tumor cells <5%
  • Isolated RNA<500ng

结局指标

主要结局

correlation analysis

时间窗: Janyary 1, 2019-December 31, 2019

x2 value and P value of chi-square test

次要结局

  • consistency analysis(Janyary 1, 2019-December 31, 2019)

研究者

发起方
Xijing Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

LiNanlin,Ph.D, Chief Physician,Clinical Professor

Professor, Thyroid breast and vascular surgery, Principal Investigator

Xijing Hospital

研究点 (1)

Loading locations...

相似试验